Form 4: Supernus CEO Jack Khattar Reports Equity Transactions
Insider Transaction Report
Supernus Pharmaceuticals CEO Jack Khattar reported the settlement of performance share units and related tax withholdings, increasing his direct beneficial ownership.
Summary
- Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on October 2, 2025.
- Acquired 20,000 shares of common stock upon the settlement of Performance Share Units (PSUs) granted on February 19, 2021, with a transaction price of $0.
- Disposed of 7,796 shares of common stock at a price of $46.21 to satisfy tax withholding requirements related to the PSU vesting.
- Acquired 19,320 shares of common stock upon the settlement of PSUs granted on February 22, 2024, with a transaction price of $0.
- Disposed of 7,529 shares of common stock at a price of $46.21 to satisfy tax withholding requirements related to the PSU vesting.
- Following these transactions, direct beneficial ownership stands at 1,185,228 shares of common stock.
- Indirect beneficial ownership remains at 1,005,600 shares of common stock held by the KBT Trust.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of insider equity transactions (vesting and tax withholding) and does not inherently convey positive or negative sentiment regarding the company's operational or financial performance.
Positives
- The settlement of Performance Share Units indicates that individual performance objectives, established on April 30, 2021, and June 24, 2024, were achieved by the Reporting Person.
Negatives
- A total of 15,325 shares of common stock were withheld by the company to cover tax obligations, reducing the net shares received from PSU settlements.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, specifically the vesting and settlement of performance-based equity awards. It does not provide information on broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency into executive compensation and changes in insider ownership, which is a standard governance practice.
Key Dates
| Date | Description |
|---|---|
| February 19, 2021 | Performance Share Units (PSUs) were granted to the Reporting Person. |
| April 30, 2021 | Individual performance objectives were established for the PSUs granted on February 19, 2021. |
| February 22, 2024 | Performance Share Units (PSUs) were granted to the Reporting Person. |
| June 24, 2024 | Individual performance objectives were established for the PSUs granted on February 22, 2024. |
| October 2, 2025 | Date of reported transactions (settlement of PSUs and tax withholdings). |
| October 3, 2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
SUPN, Supernus Pharmaceuticals, Jack Khattar, Form 4, Insider Transaction, Performance Share Units, Equity, CEO, Director, Stock Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.